Entity
  • Sensorion

    Created in 2009
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    529 6,743
  • Activities

  • Technologies

  • Entity types

  • Location

    Rue du Professeur Joseph Anglada, 34090 Montpellier, France

    Montpellier

    France

  • Employees

    Scale: 11-50

    Estimated: 77

  • SIREN

    512757725
  • Engaged corporates

    15
    9 6
  • Added in Motherbase

    6 years, 2 months ago
Description
  • Value proposition

    Our mission: find solutions for hearing disorders

    Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders

    Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.

    Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

    gene therapy, small molecule, and inner ear

  • Original language

    Our mission: find solutions for hearing disorders

    Sensorion est une société biotechnologique pionnière au stade clinique dédiée au développement de thérapies innovantes pour restaurer, traiter et prévenir dans le domaine des pertes d’audition

  • Sensorion - Live Life with Unlimited Connections

    Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies (gene therapy and small molecule) to restore, treat and prevent hearing loss disorders

  • https://www.sensorion.com/en/
Corporate interactions BETA
Corporate TypeTweets Articles
NEFTYS
NEFTYS
Finance, Financial Services
NEFTYS
Finance, Financial Services
Capitalistic
Partnership
Event

3 May 2019


La Tribune
La Tribune
Media, Newspapers
La Tribune
Media, Newspapers
Other

30 Oct 2017


France Digitale
France Digitale
Startup accelerator & VC, Non-profit Organizations
France Digitale
Startup accelerator & VC, Non-profit Organizations
Other

6 Dec 2022


BIC de Montpellier
BIC de Montpellier
Government Administration
BIC de Montpellier
Government Administration
Not capitalistic
Not partnership
Event

8 Oct 2018

29 Jul 2024



Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Capitalistic
Partnership
Not event

16 Sep 2021

11 Apr 2024



Similar entities
Loading...
Loading...
Social network dynamics